The use of nanometal oxides in nanoagronomy has garnered considerable attention due to their excellent antifungal and plant growth promotion properties. Hybrid nanometal oxides, which combine the strengths of individual nanomaterials, have emerged as a promising class of materials. In this study, nanomagnesium oxide (n-MgO) and hybrid magnetic nanomagnesium oxide (m/n-MgO) were successfully synthesized via the ultrasound-mediated sol-gel method. Characterization results, including TGA, XRD, VSM, and FTIR, confirmed the successful synthesis of m/n-MgO. Both n-MgO and m/n-MgO underwent antifungal assays and plant growth promotion ability studies, benchmarked against the conventional fungicide-copper oxychloride. This study bridges a significant gap by simultaneously reporting the antifungal properties of both n-MgO and m/n-MgO and their impact on plant growth. The disc diffusion assay suggested that the antifungal activity of n-MgO and m/n-MgO against F. oxysporum was inversely related to the particle size. Notably, n-MgO exhibited superior antifungal performance (lower minimum inhibitory concentration (MIC)) and sustained efficacy compared with m/n-MgO, owing to distinct antifungal mechanisms. Nanorod-shaped MgO, with a smaller size (8.24 ± 5.61 nm) and higher aspect ratio, allowed them to penetrate the fungal cell wall and cause intercellular damage. In contrast, cubical m/n-MgO, with a larger size (20.95 ± 9.99 nm) and lower aspect ratio, accumulate on the fungal cell wall surface, disrupting the wall integrity, albeit less effectively against F. oxysporum. Moreover, in plant growth promotion studies, m/n-MgO-treated samples exhibited a 15.7% stronger promotion effect compared to n-MgO at their respective MICs. In addition, both n-MgO and m/n-MgO outperformed copper oxychloride in terms of antifungal and plant growth promoting activities. Thus, m/n-MgO presents a promising alternative to conventional copper-based fungicides, offering dual functionality as a fungicide and plant growth promoter, while the study also delves into the antifungal mechanisms at the intracellular level, enhancing its novelty.
Insulin resistance is one of the major factors that leads to type 2 diabetes. Although insulin therapies have been shown to overcome insulin resistance, overweight and hypoglycemia are still observed in most cases. The disadvantages of insulin therapies have driven the interest in developing novel curative agents with enhanced insulin resistance reversibility. Magnesium deficiency has also been recognized as a common problem which leads to insulin resistance in both type 1 and 2 diabetes. Oxide nanoparticles demonstrate highly tunable physicochemical properties that can be exploited by engineers to develop unique oxide nanoparticles for tailored applications. Magnesium supplements for diabetic cells have been reported to increase the insulin resistance reversibility. Hence, it is hypothesized that magnesium oxide (MgO) nanoparticles could be molecularly engineered to offer enhanced therapeutic efficacy in reversing insulin resistance. In the present work, morphologically different MgO nanoparticles were synthesized and evaluated for biophysical characteristics, biocompatibility, cytotoxicity, and insulin resistance reversibility. MTT assay revealed that hexagonally shaped MgO nanoparticles are less toxic to 3T3-L1 adipose cells (diabetic) compared with spherically and rod-shaped MgO nanoparticles. MTT assays using VERO cells (normal, non-diabetic) showed that 400 μg/ml of hexagonal MgO nanoparticles were less toxic to both diabetic and non-diabetic cells. DNS glucose assay and western blot showed that hexagonally shaped MgO nanoparticles had reversed 29.5% of insulin resistance whilst fluorescence microscopy studies indicated that the insulin resistance reversal is due to the activation of intracellular enzymes. The probable mechanism for MgO nanoparticles to induce cytotoxic effect and insulin resistance reversal is discussed.
In 2018, Kidney Disease: Improving Global Outcomes (KDIGO) published a clinical practice guideline on the prevention, diagnosis, evaluation, and treatment of hepatitis C virus (HCV) infection in chronic kidney disease (CKD). The guideline synthesized recent advances, especially in HCV therapeutics and diagnostics, and provided clinical recommendations and suggestions to aid healthcare providers and improve care for CKD patients with HCV. To gain insight into the extent that the 2018 guideline has been adopted in Asia, KDIGO convened an HCV Implementation Summit in Hong Kong. Participants included nephrologists, hepatologists, and nurse consultants from 8 Southeast Asian countries or regions with comparable high-to-middle economic ranking by the World Bank: mainland China, Hong Kong, Japan, Malaysia, Singapore, South Korea, Taiwan, and Thailand. Through presentations and discussions, meeting participants described regional practice patterns related to the KDIGO HCV in CKD guideline, identified barriers to implementing the guideline, and developed strategies for overcoming the barriers in Asia and around the world.